Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery

Lauren Willis, Don Hayes, Heidi M. Mansour

Research output: Contribution to journalReview article

73 Scopus citations

Abstract

Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.

Original languageEnglish (US)
Pages (from-to)251-262
Number of pages12
JournalLung
Volume190
Issue number3
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Keywords

  • Asthma
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Lung cancer
  • Pulmonary nanomedicine
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery'. Together they form a unique fingerprint.

  • Cite this